drug · small molecule
mirdametinib
Phase 2updated 3mo agoby SpringWorks Therapeutics Inc🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.
targets
Dual specificity mitogen-activated protein kinase kinase 1Dual specificity mitogen-activated protein kinase kinase 2
all catalysts(0)
nothing on the calendar yet
Trials studying mirdametinib
- phase2MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
- phase2Mirdametinib + BGB-3245 in Advanced Solid Tumors
- phase2A Study of Mirdametinib in People With Central Nervous System Tumors
- phase2Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
- phase1Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
- phase1To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants
- —Individual Patient Compassionate Use of Mirdametinib
- phase2A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 4m ago
Found something off?
comments(0)
5-min edit window · permanent after that